Point72 Asset Management
ENTA icon

Point72 Asset Management’s Enanta Pharmaceuticals ENTA Stock Holding History

Point72 Asset Management’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-438,939
Closed -$6.92M – 3966
2025
Q4 		$6.92M Buy
438,939
+138,939
+46% +$1.76M 0.01% 1584
2025
Q3 		$3.59M Buy
+300,000
New +$2.4M 0.01% 1193
2024
Q4 		– Sell
-87,190
Closed -$903K – 2170
2024
Q3 		$903K Buy
+87,190
New +$1.14M ﹤0.01% 1454
2023
Q4 		– Sell
-25,932
Closed -$290K – 2326
2023
Q3 		$290K Buy
25,932
+17,732
+216% +$286K ﹤0.01% 1664
2023
Q2 		$175K Sell
8,200
-3,768
-31% -$111K ﹤0.01% 1460
2023
Q1 		$484K Buy
+11,968
New +$571K ﹤0.01% 1239
2022
Q3 		– Sell
-28,700
Closed -$1.36M – 1484
2022
Q2 		$1.36M Buy
+28,700
New +$1.56M 0.01% 1017
2019
Q3 		– Sell
-400
Closed -$34K – 1208
2019
Q2 		$34K Buy
+400
New +$36K ﹤0.01% 1209
2018
Q4 		– Sell
-8,400
Closed -$718K – 1028
2018
Q3 		$718K Buy
+8,400
New +$841K ﹤0.01% 892
2017
Q2 		– Sell
-56,200
Closed -$1.73M – 873
2017
Q1 		$1.73M Buy
+56,200
New +$1.75M 0.01% 683

Other funds holding ENTA

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
SSC
Spruce Street Capital New York $416M AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Point72 Asset Management's ENTA Position: Q1 2026 in Review

Point72 Asset Management sold out of Enanta Pharmaceuticals (ENTA) in Q1 2026, closing a stake of 438,939 shares — an estimated $6.92M sold.

Point72 Asset Management first reported a position in ENTA in Q1 2017 and held it in 10 quarters. The position peaked at $6.92M in Q4 2025. 132 funds tracked by Wall St. Rank hold ENTA as of Q1 2026.

  • Point72 Asset Management reported no remaining Enanta Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Point72 Asset Management sold 438,939 Enanta Pharmaceuticals shares in Q1 2026, an estimated $6.92M.
  • Point72 Asset Management first reported a position in Enanta Pharmaceuticals in Q1 2017 and held it in 10 quarters.
  • Point72 Asset Management's Enanta Pharmaceuticals position peaked at $6.92M in Q4 2025.
  • 132 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q1 2026.

Based on Point72 Asset Management's 13F filing for Q1 2026, filed 15 May 2026.